Last reviewed · How we verify
NCT04073485
Microwave Ablation for Uterine Fibroids
NA trial testing Microwave ablation in Uterine Fibroid in 6 participants. Terminated before completion.
9 March 2023
Quick facts
| Lead sponsor | Chinese University of Hong Kong |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 5 September 2019 |
| Primary completion | 9 March 2023 |
| Estimated completion | 31 March 2023 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- Microwave ablation
Conditions studied
- Uterine Fibroid — all drugs for Uterine Fibroid →
Sponsor
Chinese University of Hong Kong
Who can join
Adults 30 to 50, female only, with Uterine Fibroid. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is aimed to evaluate the clinical safety and effectiveness of Microwave ablation (MWA) in treating patients with uterine fibroid.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04073485
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Microwave ablation
Trials testing the same drug.
- NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting
- NCT06969014 — Transbronchial MWA for Pulmonary Tumors · NA · recruiting
- NCT06086002 — Clinical Feasibility of Microwave Ablation Using Two Channel Microwave Generator and Two Antennas for Small Hepatocellul · NA · completed
- NCT05887154 — Non Surgical Treatment (Microwave Ablation) of Breast Cancer · NA · unknown
- NCT05265169 — Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM) · NA · recruiting
Other recruiting trials for Uterine Fibroid
Currently open trials in the same condition.
- NCT07173127 — The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemos · NA · recruiting
- NCT06705075 — Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE · Phase 2 · recruiting
- NCT06244251 — Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids · NA · active not recruiting
- NCT05386615 — Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids · recruiting
Other Chinese University of Hong Kong trials
Trials by the same sponsor.
- NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
- NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
- NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
- NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
- NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04073485 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
- Last refreshed: 3 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04073485.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing